Paper Details

  1. Home
  2. Paper Details

Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.

Author: AndersenJ W, BergD T, MayerR J, RubinE H, SchifferC A, StoneR M

Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Patients with elevated serum creatinine, older age, and high alkaline phosphatase levels may be at increased risk for neurotoxicity associated with high-dose cytarabine treatment.
Paper Details　
Original Abstract of the Article :
PURPOSE: We analyzed pretreatment characteristics of patients with postremission acute myeloid leukemia (AML) treated with high-dose cytarabine (HIDAC) during a recent Cancer and Leukemia Group B (CALGB) trial to determine risk factors associated with HIDAC neurotoxicity. PATIENTS AND METHODS: One ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1992.10.6.948

データ提供：米国国立医学図書館（NLM）

Risk Factors for High-Dose Cytarabine Neurotoxicity: An Analysis of a Cancer and Leukemia Group B Trial in Patients with Acute Myeloid Leukemia

This study examines the complex world of [acute myeloid leukemia (AML) treatment], a field that is constantly seeking to optimize treatment strategies while minimizing adverse effects. The researchers, analyzing data from a [Cancer and Leukemia Group B (CALGB) trial], aimed to identify the [risk factors associated with high-dose cytarabine (HIDAC) neurotoxicity]. Their findings revealed significant associations between [neurotoxicity] and specific [patient characteristics] such as [age, elevated serum creatinine, and alkaline phosphatase (AP)]. This study provides valuable insights into the [potential for individualizing treatment approaches] to minimize the risk of neurotoxicity in AML patients receiving HIDAC.

Identifying the Desert's Hidden Dangers: Risk Factors for HIDAC Neurotoxicity

This study sheds light on the importance of considering [patient-specific factors] when administering [HIDAC] treatment. By identifying these risk factors, clinicians can potentially tailor treatment strategies to minimize the likelihood of neurotoxicity, thereby enhancing patient safety and improving treatment outcomes.

A Journey Through the Landscape of Cancer Treatment: Understanding HIDAC Neurotoxicity

Navigating the desert of cancer treatment requires a keen eye for detail and a deep understanding of the terrain. This study highlights the importance of recognizing potential pitfalls in the form of [HIDAC neurotoxicity]. By recognizing the risk factors associated with this adverse event, clinicians can better guide patients through their treatment journey, minimizing risks and promoting optimal health outcomes.

Dr.Camel's Conclusion

This study identifies age, elevated serum creatinine, and alkaline phosphatase as significant risk factors for high-dose cytarabine neurotoxicity in patients with acute myeloid leukemia. These findings can inform treatment decisions, allowing for individualized approaches to minimize neurotoxicity and optimize treatment outcomes.
Date :
  1. Date Completed 1992-06-25
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

1588374

DOI: Digital Object Identifier

10.1200/JCO.1992.10.6.948

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.